# NCT02773849 (NCT02773849)

> ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02773849
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Ferring Pharmaceuticals
- Conditions: Superficial Bladder Cancer
- Interventions: ADSTILADRIN
- Enrollment: 157
- Primary outcome: Number of Patients With a Complete Response Rate Based on Patients With Carcinoma in Situ (CIS), With or Without Concomitant High-grade Ta or T1 Papillary Disease.

## Indexed commentary on NCT02773849 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct02773849